Researchers can't fully explain why IGF LR3 outperforms its natural counterpart in preclinical models. Engineered in the 1990s with an arginine substitution and N terminal extension, this synthetic IGF 1 analog shows reduced IGFBP binding IGF 1 LR3 GLP 1 and peptides are changing the conversation in modern medicine. What once seemed like separate innovations are now becoming part of a much bigger shift in how physicians think about metabolism, longevity, IGF 1 LR3 (1 MG) Sigma Compounds